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A substantial excess risk of lymphomas and nonmelanoma skin cancer has been demonstrated following organ transplantation. Large
sample size and long follow-up time may, however, allow more accurate risk estimates and detailed understanding of long-term
cancer risk. The objective of the study was to assess the risk of cancer following organ transplantation. A nationwide cohort study
comprising 5931 patients who underwent transplantation of kidney, liver or other organs during 1970–1997 in Sweden was
conducted. Complete follow-up was accomplished through linkage to nationwide databases. We used comparisons with the entire
Swedish population to calculate standardised incidence ratios (SIRs), and Poisson regression for multivariate internal analyses of
relative risks (RRs) with 95% confidence intervals (CI). Overall, we observed 692 incident first cancers vs 171 expected (SIR 4.0; 95%
CI 3.7–4.4). We confirmed marked excesses of nonmelanoma skin cancer (SIR 56.2; 95% CI 49.8–63.2), lip cancer (SIR 53.3; 95% CI
38.0–72.5) and of non-Hodgkin’s lymphoma (NHL) (SIR 6.0; 95% CI 4.4–8.0). Compared with patients who underwent kidney
transplantation, those who received other organs were at substantially higher risk of NHL (RR 8.4; 95% CI 4.3–16). Besides, we
found, significantly, about 20-fold excess risk of cancer of the vulva and vagina, 10-fold of anal cancer, and five-fold of oral cavity and
kidney cancer, as well as two- to four-fold excesses of cancer in the oesophagus, stomach, large bowel, urinary bladder, lung and
thyroid gland. In conclusion, organ transplantation entails a persistent, about four-fold increased overall cancer risk. The complex
pattern of excess risk at many sites challenges current understanding of oncogenic infections that might become activated by
immunologic alterations.
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Previous epidemiological studies have reported an overall three–
five-fold increased risk of neoplasias among transplanted patients
compared with the general population (Hoover and Fraumeni,
1973; Kinlen et al, 1979; Birkeland et al, 1995, 2000; Hoshida et al,
1997; Kyllonen et al, 2000; Lindelof et al, 2000). The malignancies
most consistently associated with organ transplantation include
nonmelanoma skin cancer and lymphoproliferative malignancies
(Hoover and Fraumeni, 1973; Kinlen et al, 1979; Blohme and
Brynger, 1985; Barr et al, 1989; Kinlen, 1992; Opelz and Henderson,
1993; Birkeland et al, 1995, 2000; Bouwes Bavinck et al, 1997;
Hoshida et al, 1997; Kyllonen et al, 2000; Lindelof et al, 2000; Penn,
2000). There is limited and somewhat conflicting evidence of any
relationship between other cancers and transplantation (Hoover
and Fraumeni, 1973; Porreco et al, 1975; Kinlen et al, 1979; Blohme
and Brynger, 1985; Barr et al, 1989; Kinlen, 1992; Opelz and
Henderson, 1993; Penn, 1993, 2000; Birkeland et al, 1995, 2000;
Bouwes Bavinck et al, 1997; Hoshida et al, 1997; Kyllonen et al,
2000; Lindelof et al, 2000). Several previous studies were hampered
by small size and short follow-up times resulting in lack of
statistical precision. Moreover, only few studies (Hoover and
Fraumeni, 1973; Kinlen et al, 1979; Birkeland et al, 1995, 2000;
Hoshida et al, 1997; Kyllonen et al, 2000) were population based,
allowing valid comparisons with the reference population from
which the cancer cases arose. In an attempt to further qualify and
quantify the risk of cancer following organ replacement, we
expanded a previously analysed (Lindelof et al, 2000) large
population-based nationwide cohort study in Sweden with
virtually complete follow-up.
MATERIAL AND METHODS
This study was approved by the Ethical Committee at the
Karolinska Institutet, Stockholm, Sweden.
The Swedish in-patient register
Since 1965, the National Board of Health and Welfare has collected
data on individual hospital discharges in the in-patient register,
described in detail elsewhere (Nyren et al, 1995). The proportion of
the Swedish population covered by this register increased from
60% in 1969 to 85% in 1983, and 100% from 1987 onwards. Each
record contains up to eight discharge diagnoses, coded according
to the seventh revision of the International Classification of Received 20 February 2003; revised 2 July 2003; accepted 2 July 2003
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yDiseases (ICD-7) 1964–1968, the eighth revision (ICD-8) 1969–
1986 and the ninth revision (ICD-9) thereafter. Furthermore, each
record contains up to 10 surgical codes, assigned according to the
Swedish Classification of Operations and Major Procedures (Nyren
et al, 1995).
The individually unique 10 digit national registration number
ascribed to every Swedish citizen ensures accurate identification
and follow-up of each patient who has undergone organ
transplantation. When the in-patient register was evaluated for
validity and completeness, codes for surgical procedures were
correct for 98% of the records (Nilsson et al, 1994).
The Swedish Cancer Registry
The Swedish Cancer Registry, started in 1958, receives reports of
all incident malignant tumours diagnosed in Sweden, but does not
take into account information from death certificates (The Swedish
Cancer Registry, 2001). Reporting by both diagnosing physicians
and pathologists is mandatory by law, resulting in registration of
more than 98% of all incident tumours, with histological
verification of 97% of the tumours. During the years of follow-
up for this study, the ICD-7 was used to classify all incident
cancers as specified in Table 2. As chronic lymphocytic leukaemias
(ICD-7: 204.1) belong to the non-Hodgkin’s lymphomas (Harris
et al, 1994), they were included in this group. The nonmelanoma
skin cancer group (ICD-7: 191) does not include basal cell
carcinomas since these are not reported to the Swedish Cancer
Register.
Definition of study cohort
In Sweden, a few kidney transplantations were accomplished
during the late 1960s but this activity first became routine during
the 1970s (Figure 1). Organ transplantation is only performed at
four specialised centres belonging to public university hospitals; as
a result, private in-patient treatment is nonexistent. Therefore,
hospital-provided medical services associated with organ trans-
plantation are, in effect, population based. From the in-patient
register, we selected all 6457 patients who were hospitalised during
1970–1997 for organ transplantation. Two of four centres (Stock-
holm and Gothenburg) were not covered by the in-patient registry
until 1972 and onwards. Some 50 organ transplantations
performed at these centres during 1970 and 1971 were therefore
not included in our study cohort (Lindelof et al, 2000) unless they
were retransplanted after 1971; if so, the date of retransplantation
would be erroneously recorded as the first transplantation. The
surgical codes used for selection were the following: 6070 (kidney),
5530, 5531 (pancreas), 5200, 5202 (liver), 3590 (lung) and 3085
(heart).
The date of first recorded transplantation marked entry into the
cohort. We excluded patients with a previous history of any cancer
(n¼77) or cancers reported within 30 days after transplantation
(n¼179), patients with unknown transplantation codes (n¼258)
or mismatching transplantation dates (n¼12). Following these
exclusions, a total of 5931 eligible patients treated with transplan-
tation of the kidney, liver, heart, lung, pancreas or a combination
of solid organs were thus available for follow-up and further
analyses.
Follow-up
The in-patient register was used only to characterise patients with
organ transplantation at entry into the cohort. Linkage with the
Death register, Register of Population changes and Swedish Cancer
Register, respectively, provided information on vital status,
emigration and cancer incidence in the cohort during follow-up.
We had no reliable information about explantation of organs after
the index operation. The follow-up began 30 days after transplan-
tation, in order to exclude prevalent cancers, and continued until
diagnosis of cancer, date of death or end of follow-up on 31
December, 1997, whichever occurred first.
Analyses
Expected numbers of cancers were calculated by multiplying the
age, gender and calendar-year-specific risk time by the corre-
sponding cancer incidence rates of the general Swedish population.
The standardised incidence ratio (SIR), the ratio of the observed to
the expected number of incident cancers, was used to estimate the
relative risk (RR) of tumours for different categories. We only
counted first cancers (since completeness of reporting second
primary malignancies has not been validated), and disregarded
prevalent cancers detected incidentally at autopsy (because bias
would be introduced if autopsy rates differ between patients with
organ transplantation and the general population), both in the
cohort and in the expected rates. Confidence intervals of
standardised incidence ratio were calculated assuming that the
observed number of events followed a Poisson distribution
(Breslow and Day, 1987). The observed number of all cancers,
nonmelanoma skin cancers, lip cancers and non-Hodgkin’s
lymphomas (NHLs) – stratified according to all the combinations
of the variables given in Table 4 were analysed by Poisson
regression with the logarithm of the expected number as an offset
term. These analyses yield an assessment of the independent effect
of each variable adjusting for potential confounding factors of the
others. These analyses were used to assess the statistical
significance of each variable, and the results are presented as
RRs representing standardised incidence ratios.
RESULTS
Overall findings
Selected characteristics of the cohort members are shown in
Table 1. A total of 3592 male and 2339 female patients were
studied. The vast majority received a kidney transplant (84.3%).
The median age at transplantation was 46 years and the mean
follow-up time was 6.8 years, yielding a total of 40360 person-years
of follow-up. Figure 1 illustrates the number of patients included
per calendar year, showing a successive increase from approxi-
mately 100 transplantations per year in the early 1970s to 300
during the 1990s. Through 1984, the cohort only included patients
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Figure 1 Total number of patients undergoing organ transplantation in
Sweden per year during 1970–1997. The dark bars show number of
transplantations other than kidney.
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number of other organ transplantations were performed and
corresponded to about 30% of all transplants from the early 1990s.
Table 2 summarises the SIRs for different cancer sites following
organ transplantation. Overall, we observed 692 primary cancers
(counting first cancer at each site) vs 171 expected, yielding an SIR
of 4.0 (95% CI¼3.7–4.4). Table 3 summarises the SIRs for selected
cancers with adequate numbers for analysis stratified by type of
transplantation. The overall cancer risk does not differ signifi-
cantly between the groups. The risk of developing lip- and
nonmelanoma skin cancer is notably higher among renal
transplant patients, although this comparison is most likely
confounded by the shorter follow-up time among nonrenal
transplant patients. Multivariate analysis (Table 4) indicated that
this excess risk remained stable during the entire follow-up period.
The excess risk decreased monentously with increasing age and
was 2.5-fold higher among patients aged less than 40 compared
with those who were 60 years or older at transplantation. Relative
Risk was also significantly higher in men than in women. Lastly,
we compared the overall excess cancer risk in relation to the type
of transplanted organ and found slightly lower overall risk
following kidney transplantation compared to transplantation of
other organ(s) (Table 4).The cumulative risk of developing any
malignancy was 13.6% (95% CI¼12.4–15.0) 10 years, and 31.8%
(95% CI¼28.4–35.3) 20 years after transplantation (Figure 2).
Head and neck region and gastrointestinal tract
We found a significant almost six-fold excess risk for cancer of the
oral cavity based on 11 observed cases (Table 2). The excess was
highest for cancer of the tongue (SIR¼10.7; 95% CI 4.3–22.1).
Based on small numbers, we also found consistent, albeit
statistically nonsignificant about three-fold elevated risks for
cancer of other parts of the oral cavity and the head and neck
region such as salivary glands, floor of the mouth, pharynx and
larynx.
A three-fold, significantly increased risk was revealed for
oesophageal cancer based on five cases (Table 2). Two of these
patients were diagnosed with adenocarcinoma and three with
squamous cell carcinomas. Moreover, risk for gastric cancer was
increased two-fold.
Although based on small numbers, the risk seemed to be higher
for cancer diagnosed in the proximal part of the stomach
(SIR¼4.4, 95% CI¼1.2–11.3) than in the distal parts (SIR¼2.2,
95% CI¼0.6–5.6).
Similar to the stomach, we found an about two-fold excess risk
for cancer of the colon and rectum (Table 2). All colon cancers
were adenocarcinomas. The excess risk appeared unequally
distributed along the large bowel; SIR for the right-sided colon
was 3.3 (95% CI¼1.9–5.4), whereas SIR for the left-sided colon
(including descending and sigmoid colon) was 1.8 (95% CI¼0.7–
3.6). For rectal cancer, nine cases were adenocarcinomas
(SIR¼1.4, 95% CI¼0.7–2.6). Four were squamous cell carcino-
mas, and three of them occurred in women. Since the latter
category represents anal cancer, they were analysed separately
(SIR¼10.2; 95% CI¼2.8–26.0). We found no increased risk of
cancer of the liver and pancreas (Table 2).
Urogenital tract
The observed numbers of endometrial (corpus uteri) cancers were
close to expected and we found a small statistically non-significant
Table 1 Characteristics of 5931 patients who underwent organ
transplantation in Sweden 1970–1997
Characteristics No. of
subjects Proportion
Person-
years
Total 5931 100 40360
Transplanted organ
Kidney 5004 84.3 36963
Liver 394 6.6 1254
Heart 236 3.9 960
Lung 117 1.9 324
Pancreas 26 0.4 98
Combination of organs 154 2.5 759
Age-distribution at entry No. of subjects Proportion (%)
o40 2 262 38
40–49 1 412 24
50–59 1 487 25
60+ 770 13
Gender
Males 3 592 61
Females 2 339 39
Years Range
Median age at transplantation 46 0–84
Mean follow-up time 6.8 0–26.8
Table 2 Cancer risk following organ transplantation in Sweden, 1970–
1997
Cancer site (ICD-7) Observed
no. cases
SIR 95% CI
Overall 692 4.0 3.7–4.4
Lip (140) 40 53.3 38.0–72.5
Oral cavity (141–144) 11 5.5 2.7–9.8
Pharynx (145–146) 3 3.1 0.6–9.1
Oesophagus (150) 5 3.2 1.1–7.5
Stomach (151) 12 2.3 1.2–4.1
Small intestine (152) 1 1.1 0.0–6.2
Colon (153) 25 2.3 1.5–3.4
Rectal (154.0+154.1) 14 1.9 1.0–3.2
Adenocarcinomas 9 1.4 0.7–2.6
Squamous cell carcinoma 4 10.2 2.8–26.0
Liver, primary (155) 4 1.1 0.3–2.8
Pancreas (157) 4 0.9 0.3–2.3
Nose, middle ear (160) 2 6.8 0.8–24.5
Larynx (161) 3 2.5 0.5–7.3
Lung (162) 24 1.7 1.1–2.5
Mediastinum (164) 1 42.9 1.1–239
Breast (170) 24 1.0 0.6–1.5
Cervix uteri (171) 5 2.0 0.7–4.7
Cervix in situ 52 1.3 1.0–1.8
Ovary (175) 9 2.0 0.9–3.8
Vulva and vagina (176) 11 20.9 10.4–37.4
Vulva 9 26.2 12.0–49.8
Vagina 2 16.4 2.0–59.3
Prostate (177) 20 1.1 0.7–1.7
Testis (178) 3 2.3 0.5–6.6
Kidney (180) 28 4.9 3.3–7.1
Bladder (181) 20 2.3 1.4–3.6
Malignant melanoma (190) 14 1.8 1.0–3.0
Nonmelanoma skin cancer (191) 278 56.2 49.8–63.2
Eye (192) 1 2.0 0.0–10.9
Brain (193) 7 1.0 0.4–2.1
Thyroid (194) 6 3.8 1.4–8.2
Connective tissue (197) 3 2.3 0.5–6.7
Non-Hodgkin’s lymphoma (200+202+204.1) 45 6.0 4.4–8.0
Hodgkin’s disease (201) 2 2.2 0.3–8.1
Multiple myeloma (203) 6 2.7 1.0–5.9
Lymphocytic leukaemia (204) 3 1.8 0.4–5.1
Myeloic leukaemia (205) 5 2.9 0.9–6.7
Observed number of cases, SIR (SIR) and 95% confidence intervals (CI) by cancer site
and type.
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incidence of carcinoma in situ of the cervix was increased only
marginally. In contrast, risk for malignancies in the vulva and
vagina were markedly increased (Table 2). Of these cases, nine
were vulva (SIR¼26.2; 95% CI¼12.0–49.8) and two were vaginal
cancers (SIR¼16.4; 95% CI¼2.0–59.3).
There was an almost five-fold increased risk of kidney cancer
subsequent to organ transplantation. Of these, 19 originated in the
renal parenchyma (SIR¼4.1; 95% CI¼2.5–6.4), whereas six were
of pelvic origin (SIR¼10.5; 95% CI¼3.9–22.9). An over two-fold
statistically significant risk of bladder cancer was revealed; only
one of 20 cases was localised in the urethra, whereas the rest
occurred in the bladder or at multiple sites. Of the cases, 17 were of
transitional cell origin.
Lip and skin cancer
We found an about 50-fold excess risk of lip cancer (Table 2).
Further multivariate analyses revealed no trend with duration of
follow-up, but a significantly higher excess among patients
younger than 50 years at transplantation compared to those 50
years or older. Women were at higher risk compared to men,
although not significantly. We had limited power to detect any
difference in risk related to the type of organ transplanted
(Table 4).
A markedly increased risk of nonmelanoma skin cancer was
found among the cohort members (SIR¼56.2, 49.8–63.2), whereas
the excess risk of malignant melanoma was modest and statistically
not significant (SIR¼1.8; 95% CI 1.0–3.0). Multivariate analyses
revealed that relative risk for nonmelanoma skin cancer remained
relatively constant during 1 or more years of follow-up, and was
strongly inversely related to age at transplantation. There was no
significant difference between men and women, nor between those
undergoing kidney transplantation compared with transplantation
with other organs (Table 4). The cumulative risk of developing
Table 3 Cancer risk following organ transplantation in Sweden 1970–
1997
Cancer site (ICD-7)
Observed
no. cases SIR 95% CI
Non-kidney transplants SIR for selected sites
Lip (140) 1 24.8 0.6–138.6
Stomach (151) 3 12.0 2.4–35.0
Colon (153) 0 0 0.0–5.8
Rectal (154) 2 4.5 0.5–16.2
Kidney (180) 0 0 0.0–11.2
Nonmelanoma skin cancer (191) 11 34.0 17.0–60.6
Non-Hodgkin’s lymphoma (200, 204, 204.1) 18 37.3 22.1–59.1
All cancers 53 4.9 3.7–6.4
Kidney transplants SIR for selected sites
Lip (140) 39 54.8 39.0–74.9
Stomach (151) 9 1.8 0.8–3.4
Colon (153) 25 2.4 1.5–3.5
Rectal (154) 12 1.7 0.9–3.0
Kidney (180) 28 5.2 3.4–7.5
Nonmelanoma skin cancer (191) 267 57.7 51.0–65.1
Non-Hodgkin’s lymphoma (200, 204, 204.1) 27 3.8 2.5–5.6
All cancers 639 3.9 3.6–4.2
Observed number of cases, SIR (SIR) and 95% confidence intervals (CI) by cancer
site, type and transplanted organ.
Table 4 Multivariate analyses of relative risks for all cancers and selected cancer sites following organ transplantation
All cancers Nonmelanoma skin cancer Lip cancer Non-Hodgkin’s lymphoma
Obs RR 95% CI Obs RR 95% CI Obs RR 95% CI Obs RR 95% CI
Follow-up (years)
o1 93 1 ref 10 1 ref 0 0 na 16 1 ref
1–4 248 0.9 0.7–1.1 86 2.3 1.2–4.5 14 1 ref 11 0.2 0.1–0.5
5–9 200 1.0 0.8–1.3 92 2.8 1.4–5.3 19 1.6 0.8–3.2 11 0.3 0.2–0.8
10+ 151 0.9 0.7–1.2 90 2.4 1.2–4.7 7 0.6 0.3–1.6 7 0.3 0.1–0.7
Age at transplantation (years)
o39 155 2.5 2.0–3.1 71 3.8 2.7–5.4 4 1.6 0.5–5.3 9 4.8 1.6–14.7
40–49 158 1.4 1.1–1.8 51 1.5 1.0–2.2 17 2.8 1.2–6.3 14 3.5 1.2–9.8
50–59 229 1.2 0.9–1.4 90 1.4 1.0–1.9 10 1.0 0.9–1.4 17 2.1 0.8–5.9
60+ 150 1 ref 66 1 ref 9 1 ref 5 1 ref
Gender
Male 442 1.5 1.3–1.8 194 0.9 0.7–1.2 29 0.5 0.3–1.1 31 1.0 0.5–1.8
Female 250 1 ref 84 1 ref 11 1 ref 14 1 ref
Transplanted organ
Kidney 639 1 ref 267 1 ref 39 1 ref 27 1 ref
Other 53 1.4 1.0–1.8 11 0.7 0.4–1.3 1 0.5 0.1–3.5 18 8.4 4.3–16
Results shown as relative risks (RRs) and 95% confidence intervals (CI) after mutual adjustment for follow-up time, age at transplantation, gender and transplanted organ.
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Figure 2 Cumulative risk (solid line) with 95% CI (dotted line) of
developing any first malignancy, and nonmelanoma skin cancer, respectively,
following transplantation in Sweden, 1970–1997.
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years and 20.4% (95% CI¼17.2–24.6) after 20 years (Figure 2).
Haematopoeitic and other malignancies
There was a six-fold overall excess risk of NHL following organ
transplantation (Table 2). Relative risk was drastically increased
during the first year following transplantation (SIR¼19.6; 95%
CI¼11.2–31.9), whereas it remained fairly stable, about four-fold,
during all subsequent years. Renal-transplant patients had an
increased risk of developing NHL of 9.9 (95% CI 4.0–20.4) during
the first year that decreased to 3.2 (95% CI 1.9–4.9) thereafter,
whereas nonrenal transplant patients had an increased risk of 38.0
during the first year (95% CI 38.0–157.9) that decreased to 24.3
(95% CI 11.1–46.2) thereafter. Multivariate analyses confirmed
this pattern and revealed a strong inverse association with age at
transplantation, but no association with gender. Moreover,
compared with patients who underwent kidney transplantation,
those who received other organs were at eight-fold higher risk after
adjustment for follow-up time (Table 4). There was also an
indication of excess risks of other haematopoeitic malignancies,
although the analyses were based on small numbers (Table 2).
We found an increased risk of lung cancer (SIR¼1.7; 95%
CI¼1.1–2.5). Risk for thyroid cancer was increased four-fold
(Table 2) and that for other endocrine tumours was increased
eight-fold (data not shown). However, a further analysis of the
endocrine group revealed that 31 of the 32 cases were confined to
the parathyroid adenomas, presumably reflecting the established
association between chronic renal failure and hyperparathyroidism
(Gokal, 1988).
DISCUSSION
Although cancer risk following organ transplantation has been
analysed in several prospective studies, only few of them were
population based with long-term follow-up (Hoover and Fraume-
ni, 1973; Kinlen et al, 1979; Birkeland et al, 1995, 2000; Hoshida
et al, 1997; Kyllonen et al, 2000; Lindelof et al, 2000), and except
for one of the studies (Lindelof et al, 2000), none of them included
patients with another transplanted organ than a kidney. While
components of our study have been included in earlier analyses
(Birkeland et al, 1995) and chiefly in a publication focused on skin
cancer (Lindelof et al, 2000), the cohort has now been expanded
and the follow-up time added. This expansion has entailed the
largest population-based study so far allowing more precise
quantification of risk and also separate analyses of several
anatomic and histopathologic subtypes. We also had the
possibility at comparing cancer risk following transplantation of
a kidney with that of other organs, and to analyse effectively
duration of follow-up, age at transplantation and gender as
determinants of cancer risk.
Our study confirmed a four-fold overall risk of cancer following
organ transplantation and further indicated that this excess risk
remains seemingly stable during longer follow-up. Moreover, we
confirmed a significantly higher overall risk among patients
transplanted at young age, among men compared with women,
and following transplantation of organs other than a kidney
(Kinlen, 1992; Penn, 2000). For specific cancer sites, the excess risk
was most notable for nonmelanoma skin cancer, lip cancer and
NHL, which is in accordance with other investigators (Hoover and
Fraumeni, 1973; Kinlen et al, 1979; Blohme and Brynger, 1985; Barr
et al, 1989; Kinlen, 1992; Opelz and Heneerson, 1993; Birkeland
et al, 1995, 2000; Bouwes Bavinck et al, 1997; Hoshida et al, 1997;
Kyllonen et al, 2000; Lindelof et al, 2000; Penn, 2000). In the study
by Lindelo ¨f et al (2000), the SIRs included all incident cancers,
whereas in our study, we only counted the first cancer. This
possibly explains the differences in RR magnitudes between these
two studies. Novel findings in our study include the substantial
excess risk for cancer of the tongue, anus, vulva and vagina, but no
convincing excess risk for in situ or invasive cancer of the cervix as
reported previously (Porreco et al, 1975; Sillman et al, 1984), and
evidence of a higher risk for kidney cancer with pelvic origin than
that of parenchymal origin.
While we consider the internal validity of our study to be high,
several limitations should be emphasised. Since we were unable to
scrutinise almost 6000 medical records individually, we had to rely
on information from the In-patient Discharge Register. It is
difficult to reconstruct from this register accurately the course of
events following an organ transplantation which may include
explantation as well as one or several replantations. Most likely,
neither failure to censor follow-up in some patients because they
were neither transplanted nor immunosuppressed entails some
underestimation of excess risks. Notwithstanding the relatively
large size of the study, we had insufficient power to analyse several
rare malignancies and to confirm moderate excess risks. Moreover,
we could not effectively adjust for potential confounding because
we had neither data on life-style factors among organ-transplanted
patients nor among the general Swedish population that generated
the expected cancer incidence rates. About 30% of transplanted
patients have diabetes (The Swedish Registry of Vrenic Care 2000),
a disease associated with an excess risk of several malignancies
(Adami et al, 1991). Diabetes is unlikely, however, to explain our
pattern of findings because this disease is associated most strongly
with cancer of the liver (Lagiou et al, 2000) and endometrium
(Weiderpass et al, 2000), two sites for which we observed no excess
risk following transplantation. Long-term dialysis preceding
kidney transplantation is another conceivable confounder,
although studies of cancer risk in such patients have been
inconclusive (Kantor et al, 1987; Fairley et al, 1994; Maisonneuve
et al, 1999; Birkeland et al, 2000). Lastly, many of the excess risks
we observed were substantially higher than those generally found
in relation to established risk factors for the respective malig-
nancies. Hence, confounding may indeed be a limited concern and
most of the risks we observed might be attributable to the organ
transplantation and subsequent immunosuppressive therapy.
Our study was not designed to elucidate the numerous
mechanisms that have been invoked to explain the excess cancer
risk following organ transplantation (Penn, 1991). Among these,
immune modulation is the most obvious, and likely the most
important. Prevalent infection with several potentially oncogenic
viruses and bacteria, such as EBV, human papilloma virus (HPV),
HHV-8, HTLV-1, HIV and Helicobacter pylori, might become
activated by impaired immune function (Goedert, 2000). As several
of these, notably HHV-8, HTLV-1 and HIV, are rare in the Swedish
population, measurable effects on cancer risk appear unlikely.
Although EBV may account for the substantial excess risk of NHL
– appearing with a short latency and being most marked after
organ transplantation other than the kidney – the possible role of
other viruses yet to be detected is presently unknown. Although
activation of H. pylori might explain the excess risk of stomach
cancer, this bacterium appears most strongly associated with distal
stomach cancer (Huang et al, 1998) while we, if anything found
higher excess risk for proximal cancers.
Most enigmatic were our findings with regard to cancers
associated with HPV. Unknown HPV subtypes are hypothesised to
play a role in the aetiology of nonmelanoma skin cancer (Blohme
and Brynger, 1985; Barr et al, 1989; Bouwes Bavinck et al, 1997)
and defined oncogenic types are clearly causally related to cancer
of the cervix (IARC, 1995), anus (Frisch et al, 1997), vulva and
vagina (Blohme and Brynger, 1985; Alloub et al, 1989). Although
controversial, HPV has also been proposed as a risk factor for
oesophageal cancer (Galloway and Daling, 1996) as well as for head
and neck cancers (Mork et al, 2001). However, if altered immune
function entails activation of HPV infection and thereby increased
viral load, an excess risk of malignancies of the cervix should be
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observed. This leads us to hypothesise that anatomic differences in
immunologic control of HPV-harbouring target cells explains the
spectacular differences in risk for HPV-associated malignancies.
The substantial excess risk for numerous malignancies without any
established or suspected infectious aetiology further suggests that
the mechanisms by which organ transplantation increases cancer
risk may be more complicated than an infectious-driven malignant
transformation. This finding seems to challenge the established
concept that most tumours are nonimmunogenic. Moreover,
recent experimental data from immunodeficient double-knockout
mice show increased incidence of several spontaneous tumour
types (Shankaran et al, 2001).
In conclusion, we provide further evidence of an association
between organ replacement and the development of a number of
different malignancies. These results indicate the need for further
investigation as the numbers of transplant recipients increase and
their life expectancy improves. A better understanding of factors
that determine cancer risk might serve several purposes. First, an
immunosuppressive regimen could be designed to minimise
cancer risk whenever possible. Second, a better quantification of
cancer risks might facilitate early diagnoses and thereby poten-
tially improve prognosis. Lastly, detailed studies of cancer
following organ transplantation might advance our understanding
of the carcinogenic process and the role of immune surveillance
for several cancer sites and types.
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